Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.
Sixteen patients with motor neuron disease received RX77368, a TRH analogue, IV, repeatedly over 1-12 weeks (median 2 weeks). Slight to moderate improvement in bulbar function, particularly speech, was reproduced or persisted with repeated infusions in 8 of 12 responders over a median of 18 days (range 14-90) during the period of study. Cramps (5/9) and spasticity (5/8) improved for a median of 14 days (range 7-35) and 7 days (range 2-14) respectively. The highest benefit/side effect ratio was seen with 0.2 mg/kg (0.15 mg/kg in those with severe bulbar palsy) every 3-4 days. Long term studies with this analogue in MND are indicated.
Modarres-Sadeghi
H
H
Department of Neurology, Charing Cross and Westminster Medical School, Westminster Hospital, London, UK.
Rogers
H
H
Emami
J
J
Guiloff
R J
RJ
D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy; D010244:Bulbar Palsy, Progressive / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004401:Dysarthria / Q000188:drug therapy; D004576:Electromyography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000187:drug effects*; D009119:Muscle Contraction / Q000187:drug effects; D009128:Muscle Spasticity / Q000188:drug therapy; D009468:Neuromuscular Diseases / Q000188:drug therapy*; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D012131:Respiratory Insufficiency / Q000188:drug therapy; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014832:Voice Disorders / Q000188:drug therapy
D013973:Thyrotropin-Releasing Hormone; C027979:L-pyroglutamyl-L-histidyl-3,3-dimethylprolinamide; D011761:Pyrrolidonecarboxylic Acid